Sign in

You're signed outSign in or to get full access.

OP

Ocuphire Pharma, Inc. (OCUP)·Q4 2023 Earnings Summary

Executive Summary

  • Q4 revenue fell to $1.69M, down sharply year over year from $39.85M due to the absence of the large upfront license revenue recognized in Q4 2022; diluted EPS was ($0.21) vs $1.58 a year ago .
  • Sequentially, Q4 revenue declined vs Q3 ($11.94M) as Q3 included a $10M Viatris milestone tied to RYZUMVI approval; Q4 reflected primarily reimbursed R&D services and milestone timing effects .
  • Cash and cash equivalents ended Q4 at $50.5M (up from $42.4M in Q3), with runway into mid‑2025; management emphasized Phase 3 preparation for oral APX3330 in diabetic retinopathy and submission of a Special Protocol Assessment in Feb 2024 .
  • Estimates context: Wall Street consensus via S&P Global was unavailable for OCUP this quarter; no estimate comparison provided (tool retrieval failed).

What Went Well and What Went Wrong

What Went Well

  • APX3330 advanced toward Phase 3: End‑of‑Phase 2 meeting achieved FDA alignment on the registrational primary endpoint (≥3‑step binocular DRSS worsening); SPA submitted in Feb 2024 to finalize protocol/statistics .
  • RYZUMVI approved by FDA (Sept 2023) and expected U.S. launch in 1H 2024, with a $10M milestone received in 2023 under the Viatris agreement supporting cash resources .
  • Management highlighted strategic focus and confidence: “Ocuphire had a successful 2023…Our strategic focus is on the advancement of our retina pipeline…we are preparing our late-stage clinical program to progress APX3330 in diabetic retinopathy” – CEO George Magrath .

What Went Wrong

  • Revenue normalization post-license upfront: Q4 revenue was $1.69M vs $39.85M in Q4 2022 when Viatris license upfront was recognized; net swung to a Q4 2023 loss of ($4.80M) vs $33.94M prior year .
  • Operating expenses remained elevated: Q4 G&A of $3.28M and R&D of $3.84M reflect continued investment in programs and corporate build; Q4 operating loss was ($5.43M) .
  • Estimates context unavailable: Lack of S&P Global consensus estimates for OCUP limits external benchmark comparison for EPS and revenue this quarter (tool retrieval failed).

Financial Results

Quarterly Comparison (oldest → newest)

MetricQ2 2023Q3 2023Q4 2023
License & Collaboration Revenue ($USD Millions)$3.674 $11.935 $1.691
Operating Income ($USD Millions)($5.389) $6.386 ($5.429)
Net Income ($USD Millions)($4.961) $5.561 ($4.795)
Diluted EPS ($USD)($0.24) $0.25 ($0.21)

Key KPIs (quarter-end)

KPIQ2 2023Q3 2023Q4 2023
Cash and Cash Equivalents ($USD Millions)$39.977 $42.350 $50.501
Accounts Receivable ($USD Millions)$0.135 $10.132 $0.926
G&A Expense ($USD Millions)$4.340 $2.055 $3.279
R&D Expense ($USD Millions)$4.723 $3.494 $3.841

Q4 Year-over-Year Comparison

MetricQ4 2022Q4 2023
License & Collaboration Revenue ($USD Millions)$39.850 $1.691
Net (Loss) Income ($USD Millions)$33.941 ($4.795)
Diluted EPS ($USD)$1.58 ($0.21)

Notes:

  • Q3 revenue included a $10M Viatris milestone tied to FDA approval of RYZUMVI; Q4 did not repeat that level of milestone recognition .
  • 2022 Q4 revenue was driven by the Viatris license agreement signed in Q4 2022; 2023 revenue primarily reflects reimbursed R&D services plus the 2023 milestone .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Cash RunwayThrough 2025“Into 2025” (Q3 commentary) “Into mid‑2025” Maintained (refined timing)
RYZUMVI Launch Timing1H 20241H 2024 (Q3) 1H 2024 (Q4) Maintained
APX3330 Phase 3 Design2024 initiation stepsEOP2 endpoint aligned; SPA planned SPA submitted Feb 2024; timing TBD upon FDA agreement Progressed toward Phase 3
Viatris-Funded PS Programs (Presbyopia, Dim Light Vision)1H 2024 developmentViatris to continue Phase 3 in 1H 2024 Viatris to continue Phase 3 in 1H 2024 Maintained

Earnings Call Themes & Trends

Note: A Q4 2023 earnings call transcript was not found in the document catalog; Q3 included a scheduled call on Dec 5, 2023 .

TopicPrevious Mentions (Q2 & Q3)Current Period (Q4 2023)Trend
APX3330 regulatory pathQ2: EOP2 meeting scheduled for Q4 2023 ; Q3: EOP2 completed, endpoint aligned, SPA planned SPA submitted Feb 2024; preparing late-stage program Advancing toward Phase 3
RYZUMVI commercializationQ2: PDUFA 9/28/23 with $10M milestone upon approval Approved; launch expected 1H 2024 Transitioning to launch via partner
Viatris development of PSQ3: VEGA-2 met primary endpoint; Viatris to continue Phase 3 in 1H 2024 Viatris to continue Phase 3 presbyopia and dim light indications in 1H 2024 Continued partner execution
Cash runwayQ2: ~$40M cash; runway into 2025 $50.5M cash; runway into mid‑2025 Strengthened balance sheet
Corporate leadership changes—CEO appointment in Nov 2023; CFO and CS&D officer appointments in Feb 2024 Building leadership for execution

Management Commentary

  • “Ocuphire had a successful 2023, with notable achievements on the regulatory and development fronts…Our strategic focus is on the advancement of our retina pipeline, and we are preparing our late-stage clinical program to progress APX3330 in diabetic retinopathy.” – CEO George Magrath .
  • “We achieved important regulatory and clinical milestones…advancing oral APX3330 towards a registrational Phase 3 program…We now have agreement with the FDA on the Phase 3 primary endpoint…” – CEO George Magrath (Q3 update) .
  • “RYZUMVI™…approved by the FDA…Ocuphire received a $10 million milestone payment from Viatris…RYZUMVI is expected to be commercially available in the U.S. in the first half of 2024.” .

Q&A Highlights

  • A Q4 2023 earnings call transcript was not found; no Q&A content is available in the document set. Q3 included a scheduled call on Dec 5, 2023 .

Estimates Context

  • Wall Street consensus estimates via S&P Global were unavailable for OCUP this quarter; the S&P Global tool returned no mapping for the ticker, preventing retrieval. As a result, comparisons to consensus for revenue and EPS are not provided.

Key Takeaways for Investors

  • Revenue volatility is driven by partner milestone timing and license accounting; Q4’s normalization vs Q3/Q4 2022 reflects the absence of large upfront or milestone amounts in the quarter .
  • Balance sheet is solid with $50.5M cash and runway into mid‑2025, supporting Phase 3 preparation for APX3330 without near-term financing necessity signals in filings (LPC equity line remains available) .
  • Regulatory momentum: EOP2 alignment and SPA submission de-risk the Phase 3 path for APX3330; near-term catalyst is FDA SPA agreement (protocol/statistics) .
  • Commercial catalyst: RYZUMVI U.S. launch in 1H 2024 by Viatris may support ongoing partner-related economics; presbyopia and dim light vision Phase 3 programs continue under Viatris funding .
  • Expense profile indicates continued investment: Q4 G&A and R&D totaled $7.12M; monitor burn vs runway as APX3330 advances to Phase 3 .
  • Leadership build-out (CEO/CFO/CS&D appointments) suggests organizational readiness for late-stage execution and partner management .
  • Lack of published Street coverage limits estimate-based trading setups; focus on regulatory/commercial milestones (SPA agreement, launch timing) for near-term stock reaction drivers .